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Abstract Over the last decade, the zebraﬁsh has entered the ﬁeld of cardiovascular research as a new model organism. This is
largely due to a number of highly successful small- and large-scale forward genetic screens, which have led to the
identiﬁcation of zebraﬁsh mutants with cardiovascular defects. Genetic mapping and identiﬁcation of the affected
genes have resulted in novel insights into the molecular regulation of vertebrate cardiac development. More recently,
the zebraﬁsh has become an attractive model to study the effect of genetic variations identiﬁed in patients with car-
diovascular defects by candidate gene or whole-genome-association studies. Thanks to an almost entirely sequenced
genome and high conservation of gene function compared with humans, the zebraﬁsh has proved highly informative
to express and study human disease-related gene variants, providing novel insights into human cardiovascular disease
mechanisms, and highlighting the suitability of the zebraﬁsh as an excellent model to study human cardiovascular dis-
eases. In this review, I discuss recent discoveries in the ﬁeld of cardiac development and speciﬁc cases in which the
zebraﬁsh has been used to model human congenital and acquired cardiac diseases.
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1. Introduction
The zebraﬁsh offers several distinct advantages as a genetic and
embryonic model system to study cardiovascular disease. One
major advantage is that zebraﬁsh are vertebrates that can be used
for unbiased and whole-genome forward genetic screens. This
allows the identiﬁcation of novel genes that are required for cardio-
vascular development. In addition, the function of unknown genes,
identiﬁed by expression or interaction screens, can be investigated
by various reverse genetic approaches. Zebraﬁsh embryos are par-
ticular well suited for studying gene function during cardiovascular
development, because zebraﬁsh embryos are not completely depen-
dent on a functional cardiovascular system for their development. In
zebraﬁsh embryos that lack blood circulation, oxygen can still enter
the embryos and reach all tissues by passive diffusion owing to the
small size of the embryo. This feature permits the embryos to
survive the initial phase of embryonic development and allows the
analysis of embryos with severe cardiovascular defects. This is in con-
trast to avian and mammalian embryos, which die rapidly in the
absence of a functional cardiovascular system. Besides the ease of
identifying and studying genetic mutants, the optical transparency of
zebraﬁsh embryos has given new insights into various cellular
aspects of cardiovascular development. The combination of new
transgenic technologies to drive tissue-speciﬁc expression of ﬂuor-
escent proteins with sophisticated imaging technologies, such as live
imaging using single- or multi-photon confocal microscopy and single-
plane illumination microscopy, has steadily increased interest in the
zebraﬁsh embryo for the study of cardiovascular development and
disease.
Intheﬁrstpartofthisreview,Iaddressinchronologicalorderthecel-
lular and molecular events that lead to cardiogenic speciﬁcation and
differentiation, heart tissue morphogenesis and cardiac function. In
the second part, I discuss speciﬁc cases in which the zebraﬁsh has
been used to model human congenital and acquired cardiac diseases.
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2.1 Cardiogenic speciﬁcation and
differentiation
The heart is the ﬁrst organ to form and function during vertebrate
embryo development. Heart development begins with the speciﬁcation
of myocardial and endocardial progenitor cells. Cell-labelling studies
have identiﬁed two pools of myocardial progenitor cells (atrial and ven-
tricular)located inthelateralmarginalzone ateithersideoftheembryo
before gastrulationstarts
1(Figure1A). Atrialprogenitorcellsare located
more ventrally in the lateral marginal zone when compared with ventri-
cular progenitor cells.
2 The size of the myocardial progenitor pool is
restricted by retinoic acid signalling.
3 In contrast to the myocardial pro-
genitor cells, endocardial ventricular and atrial progenitors are distribu-
ted throughout the marginal zone without apparent organization.
2
The homeobox-containing transcription factor Nkx2.5 is required
for cardiogenic differentiation from Drosophila to humans. Its expression
in zebraﬁsh is initiated at the one- to three-somite stage. Induction of
nkx2.5 expression requires activation of the bone morphogenetic
protein (Bmp) pathway, as a subset of swirl/bmp2b mutant embryos
lack nkx2.5 expression.
4 However, the negative feedback loop by
which Nkx2.5 represses Bmp signalling activity in the anterior lateral
plate mesoderm (ALPM) of mouse embryos has thus far not been
studied in zebraﬁsh.
5 Importantly, it has been suggested that regulation
of nkx2.5 expression by Bmp signalling is indirect, because over-
expression of gata5 in swirl/bmp2b mutant embryos restores nkx2.5
expression.
6 Furthermore, mutant analyses have demonstrated that
Nodal signalling is required for nkx2.5 signalling and, in a similar
manner to the scenario in swirl/bmp2b mutants, nkx2.5 expression in
Nodal mutants can be restored by ectopic expression of gata5.
6
Together, these results indicate that both Bmp and Nodal signalling
induce nkx2.5 expression and cardiogenic differentiation by inducing
gata5.I n d e e d ,faust/gata5 mutant embryos have a reduction in nkx2.5
expression, resulting in smaller and bilateral myocardium.
7 Finally, the
basic helix–loop–helix transcription factor Hand2 is also required
Figure 1 Stages of cardiac development. (A) At 5 h post fertilization (hpf) the blastula (white) covers approximately 50% of the large yolk cell
(yellow). At this stage, cardiac progenitor cells are located bilaterally in the lateral marginal zone. Atrial progenitor cells (pink) are located more ven-
trally than the ventricle progenitor cells (light blue). During gastrulation, the cardiac progenitor cells move dorsally towards the mid-line to endu pi n
the anterior later plate mesoderm (ALPM). Cardiogenic differentiation is initiated in the future ventricle myocardial cells by the expression of cardiac
myosins (purple) at the 12-somite stage. During mid- and late-somite stages, the myocardial tissue expands by continuous cardiogenic differentiation
into more lateral regions of the ALPM by the cardiogenic differentiation of future atrial myocytes (orange; venous differentiation). Whilst the endo-
cardial cells (light green) have already migrated from the ALPM towards the mid-line, myocardial cells follow this behaviour slightly later. When the
bilateral heart ﬁelds fuse at the mid-line, they form a cardiac disc structure with the endocardial cells within the hole at the centre, ventricular myo-
cytes at the circumference and atrial myocytes at the periphery of the disc (D). Cardiac morphogenesis transforms the cardiac disc into a cardiac tube.
The endocardium forms the inner lining of the myocardial tube. (E) At 28 hpf, the linear heart tube has formed, with the venous pole located at the
anterior left and the arterial pole ﬁxed at the mid-line. (F) Cardiogenic differentiation continues at the arterial pole, and as a result new cardiomyo-
cytes are added to this region (purple gradient). At 36 hpf, cardiac looping has started, with a displacement of the ventricle towards the mid-line, and
the constriction at the position of the AV canal is ﬁrst visible (F). The heart tube continuous to loop and forms an S-shaped loop (G). Ellipsoid extra-
cardiac pro-epicardial cells (brown) are located near the AV canal (yellow), from where they start to cover the myocardium with an epicardial layer.
The pacemaker is present in the inner curvature of the atrium near the venous pole (dark green).
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have dramatically reduced myocardial tissue.
8 Hand2 acts downstream
of or in parallel to Nkx2.5, as nkx2.5 is normally expressed. Besides a
cell-autonomous role for Hand2 during cardiogenic differentiation,
Hand2 also has a non-cell-autonomous role during fusion of the bilat-
eral cardiac ﬁelds by repressing ﬁbronectin production (see below in
section 2.2).
9
During cardiogenic differentiation, expression of sarcomeric
myosin genes is observed in the ALPM as early as the 14-somite
stage.
10 Expression of myosin light chain polypeptide 7 (myl7, formerly
indicated as cmlc2) is initiated in few cells, with the number of cells
expressing myl7 increasing over time.
11 The myocardial cell popu-
lation is regionalized in a medial to lateral direction, with the
medial cells expressing ventricle myosin heavy chain (vmhc) and the
lateral cells expressing atrial myosin heavy chain (myh6/amhc). This
strict organization and separation of ventricular and atrial myocytes
is maintained during the later stages of cardiac development, and it
is currently unclear by what mechanism these two cell populations
are kept separated. Interestingly, expression of the atrium-speciﬁc
myosin myh6 is initiated slightly later compared with the onset of
expression of the ventricle myosin vmhc,
12 suggesting that the differ-
entiation of these two myocardial cell types is initiated at different
time points. Supporting this hypothesis, a developmental timing
assay, making use of the different maturation times for green ﬂuor-
escent protein and red ﬂuorescent protein, demonstrated that
during mid- to late somite stages there is continuous cardiogenic
differentiation in the ALPM. Cardiogenic differentiation is initiated
at the 12- to 15-somite stage [16 h post fertilization (hpf)] in the
future ventricle cells, which are located closest to the mid-line
(Figure 1B). This is followed by the differentiation of the more laterally
located future atrial cells until the 26-somite stage (22 hpf), also
referred to as venous differentiation (Figure 1C). After the linear
heart tube has been formed (30 hpf), cardiogenic differentiation con-
tinues at the arterial pole
11 (Figure 1F). This late addition of cardio-
myocytes to the arterial pole of the zebraﬁsh heart resembles the
addition of cardiomyocytes from the anterior or second heart ﬁeld
as described in amniotes.
13 The genetic pathways that regulate the
addition of cardiomyocytes to the developing heart are beginning
to be uncovered, although it is likely that different factors may be
required for differentiation of distinct subpopulations of cardiomyo-
cytes. For example, the late addition of new cardiomyocytes at the
arterial pole depends on Fgf signalling,
11,14 best demonstrated in
ace/fgf8 mutant embryos or in embryos in which Fgf signalling has
been inhibited during mid- to late-somite stages affecting the size
of the ventricle.
14 As the atrium remains largely unaffected upon
such treatments, it suggests that Fgf signalling is not regulating
venous differentiation during mid- to late-somite stages in the
ALPM. Islet-1 (Isl1) would be a good candidate for regulating the
venous differentiation in the ALPM, owing to its demonstrated role
in regulating cardiogenic differentiation of cells derived from the
second heart ﬁeld in mouse embryos. Zebraﬁsh isl1 is expressed in
the lateral-most cells of the cardiac ﬁeld.
15 Mouse and zebraﬁsh
Isl1 have different functions at the cardiac poles. In mouse
embryos, Isl1 is required for the addition of cells from the second
heart ﬁeld to both the arterial and the venous pole, whereas isl1
mutant zebraﬁsh embryos have a signiﬁcant although moderate
reduction in the cardiogenic differentiation only at the venous pole.
A possible candidate for regulating the venous differentiation in the
lateral regions of the ALPM is Bmp signalling. Bmp ligands are
known for their cardiogenic potential.
16 In addition, laf/alk8 mutant
embryos, containing a mutation in one of the Bmp type I receptors,
develop hearts with a reduced atrium, while the size of the ventricle
remains unaffected.
17,18 Analysis of temporal and spatial (in)activation
of Bmp signalling in the ALPM during cardiogenic differentiation,
together with temporal rescue of the laf/alk8 phenotype should
allow us to address this issue. Together, these data show that a
number of spatially restricted factors are required in concert to gen-
erate continuous regionalized cardiac differentiation.
2.2 Migration and fusion of the bilateral
heart ﬁelds
During gastrulation and early somite stages, the cardiac progenitor
cells converge towards the mid-line to reach their destination in the
ALPM, which requires grinch (Figure 1B). The grinch mutant, identiﬁed
in a forward genetic screen, exhibits a reduced number of myocardial
cells. Grinch, which encodes a G-coupled Apelin receptor (agtrl1b), is
expressed in the marginal zone and ALPM, while its ligand, Apelin, is
expressed in the mid-line.
19,20 Cell-labelling experiments demon-
strated that Agtrl1b and Apelin are required to enable migration of
the bilateral pools of myocardial progenitor cells towards the
mid-line, where they receive the appropriate signals to induce their
cardiogenic differentiation.
During mid- and late-somite stages, cardiogenic differentiation and
heart morphogenesis occur simultaneously, often making it difﬁcult to
attribute the function of a gene speciﬁcally to one of these processes.
In some cases, the identiﬁed factor plays a role in both processes; for
example, in the case of Hand2.
9 Independent from its role in regulating
cardiogenic differentiation, Hand2 is also required for the movement of
the cardiac ﬁelds towards the embryonic mid-line by regulating ﬁbro-
nectin levels. Analysis of cardiac fusion in natter mutant embryos
revealed that the two bilateral heart ﬁelds fail to migrate towards the
mid-line, resulting in cardia biﬁda.
21 The natter mutants harbour an inac-
tivating mutation in ﬁbronectin, demonstrating an essential role for extra-
cellular matrix ﬁbronectin during this process.
22 Fibronectin is
deposited in a thin layer at the interface of the myocardial tissue and
the yolk syncytial layer, an extra-embryonic tissue also required for
myocardial migration.
23 Indeed, analyses of a number of mutants have
helped to uncover the role of this structure in promoting cardiomyo-
cyte migration. Expression of the spinster homologue two-of-hearts/toh
in the yolk syncytial layer regulates the transport of sphingosine 1-
phosphate (s1p) from the yolk to the embryonic tissue.
24,25 In the
embryonic tissue, the s1p receptor miles apart (mil/s1p2) is required
for proper migration of the cardiac ﬁeld towards the mid-line. Further-
more, in mil/s1p2 mutant embryos, ﬁbronectin levels are reduced,
suggesting that s1p from the yolk regulates embryonic ﬁbronectin
levels to allow proper migration of the bilateral heart ﬁelds to the
mid-line.
24,26 Besides s1p, the extra-embryonic syndecan 2 (Sdc2), a
heparan sulfate proteoglycan, is also required for migration of the bilat-
eral heart ﬁelds towards the mid-line.
27 Knock-down of sdc2 in the
extra-embryonic yolk results in a reduction of ﬁbronectin at the yolk
syncytial layer–embryo interface and subsequently affects the polarity
of the myocardial cells.
2.3 Formation of the endocardium
The endocardium is derived from a distinct region in the ALPM that
also gives rise to haematopoietic cells of the primitive myeloid
lineage.
28 Using transgenic zebraﬁsh expressing different ﬂuorescent
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confocal microscopy, it was shown that endocardial cells migrate
towards the mid-line slightly before the myocardial cells do so.
28
After the bilateral myocardial heart ﬁelds have migrated in a coherent
and medial direction towards the mid-line, the peripherally localized
cardiomyocytes change their direction of movement in the anterior
and posterior direction. At this point, the myocardial cells at the pos-
terior and anterior ends of the myocardial sheet move inward
towards the endocardial cells already located at the mid-line and
thereby establish the initial circumference of the nascent heart
tube.
29 Once the bilateral heart ﬁelds have fused at the mid-line,
the cardiac tissue forms a disc, in which the future ventricle cells
are located at the circumference, the endocardial cells at the
centre, and the future atrial cells at the periphery (Figures 1D and 2A).
2.4 Formation and rotation of the
myocardial tube
Up to disc stage, the heart morphogenesis process can be regarded
as symmetrical, because there are no morphological differences
between the left and right cardiac ﬁelds (Figure 2A,C,G). However,
once the cardiac disc has formed the myocardial tissue originating
from the right cardiac ﬁeld involutes ventrally and moves towards
the anterior/left (Figure 2B,E,H). As a consequence, the original
left–right organization of the cardiac disc is transferred into a
dorsal–ventral organization of the cardiac tube (Figure 2F). Endocar-
dial cells that were located ventral to the myocardial disc will be
positioned within the lumen of the cardiac tube.
28,30,31 Four-
dimensional confocal miscroscopy combined with automated cell
tracking revealed that simultaneous with right-ﬁeld involution, the
myocardial disc rotates in a clockwise direction (Figure 2G–
I).
30,32,33 As a consequence of asymmetric involution and rotation
of the myocardial tissue, a cardiac tube is formed, with its venous
pole located at the left side and its arterial pole still at the
mid-line (Figures 1E and 2C). This directed migration of the myocar-
dial cells requires the extracellular matrix component hyaluronic
acid, which is a glycosaminoglycan produced by hyaluronan synthase
2 (has2).
32 Concomitantly with the translocation of the venous
pole towards the left side of the embryo, the heart tube also
extends during this time (Figure 2C). The polarity and epithelial
organization of myocardial cells is essential for the extension of
the cardiac tube, as loss of cell polarity proteins causes an arrest
of cardiac morphogenesis at the heart disc stage.
31,34,35
Nodal and Bmp, which belong to the transforming growth factor-
b (Tgf-b) superfamily of growth factors, are asymmetrically
expressed in the ALPM and direct asymmetric heart morphogenesis.
Disruption of Nodal signalling within the heart ﬁeld by the knock-
down of southpaw (spaw)/nodal, or randomization of spaw/nodal
expression due to immotile cilia disrupting nodal ﬂow in switch
hitter mutants resulted in a randomization in the direction of heart
morphogenesis.
30,31 Supporting these ﬁndings, the rotational move-
ment of the cardiac disc is impaired in embryos lacking the Nodal
co-receptor one-eyed pinhead/egf-cfc.
33 Prior to asymmetric involu-
tion and rotation of the cardiac disc, bmp4 is asymmetrically
expressed in the ALPM, with elevated levels of expression on the
left side.
36 Also, enhanced Bmp activity in the left ALPM was
observed using an antibody recognizing phosphorylated Smad1,5,8
proteins, which are downstream mediators of Bmp signalling.
32
Blocking Bmp signalling at the cardiac disc stage by over-expression
of the Bmp inhibitor Noggin, using a heat shock-inducible transgenic
line, prevented the leftward movement and rotation of the myocar-
dial tissue.
18,32 As asymmetric bmp4 expression is disrupted in
mutants lacking the Nodal-related genes cyclops or southpaw or
the transcription factor schmalspur/foxh1, which activates Nodal
target genes, it is conceivable that the asymmetric Bmp activation
is regulated by unilateral Nodal activity in the left ALPM.
18,36 Exper-
iments with ectopic activation of Nodal and Bmp signalling in the left
or right ALPM in Nodal and Bmp signalling mutants should address
the inter-relationship between these two pathways during asym-
metric heart morphogenesis. Cardiac extension is still observed in
embryos in which Nodal or Bmp signalling has been disrupted,
suggesting that heart tube extension and leftward displacement are
separately regulated.
Figure 2 Heart morphogenesis. Dorsal views (A–C, G, and H) and
cross-sections (D–F) of the heart ﬁeld are shown at three different
stages: 23 somites or 20.5 hpf (A,D, and G), 25 somites or 22 hpf
(B,E, and H) and 24 hpf (C,F, and I). (A–C) Double-labelling in situ
hybridization with ventricle myosin heavy chain (vmhc, red) and atrial
myosin heavy chain (amhc/myh6, blue) probes. (D–F) Cross-sections
after in situ hybridization with a cmlc2/myl7 probe (D and E)o ra
lefty2 probe (blue) with an anti-tropomyosin antibody (brown).
(G–I) Projections of confocal stacks made from a living
Tg(cmlc2:eGFP) embryo. Tracking of individual myocytes was per-
formed, and four examples are shown as yellow dots. After fusion
of the bilateral heart ﬁelds, a cardiac disc is formed, which is
located ventrally to the neural tube and endoderm (A,D, and G).
The future ventricle cells (blue cells in A and B) are located in the
central region of the disc, where they start to form a cone due to
an involution of the tissue at the right side (dashed arrows in B
and E). The future atrial cells (blue in A and B) are located at the per-
iphery of the disc. These cells are displaced towards the anterior left
and cause the future venous pole to rotate in a clockwise direction
(arrows in B, H, and I). Owing to the involution process and rotation
processes, the left cardiac ﬁeld will form the dorsal wall of the heart
tube, indicated by lefty2 expression in F. The myocytes derived from
the right cardiac ﬁeld will form the ventral wall of the cardiac tube
(lefty-negative cells in F). When the myocardial tube has formed, it
will extent anteriorly by a thus far unidentiﬁed process.
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ballooning
After the linear heart tube has formed, it bends towards the right side.
The bending is best described as a displacement of the future ventricle
so that it will be positioned at the right side of the embryonic mid-line,
while the future atrium remains positioned at the left side of the
mid-line (Figure 1F). Little is known regarding the cellular processes
that facilitate bending of the heart tube and the underlying molecular
mechanisms. Interestingly, the direction of cardiac looping is dictated
by the preceeding direction of cardiac displacement. For example,
heart tubes that extend to the right side of the embryo will ultimately
loop in the reverse direction.
36 In addition, the degree and direction
of rotation of the cardiac disc as described above is correlated with
the degree and direction of the cardiac displacement.
30,32 Importantly,
not all parts of the cardiac tube rotate equally. Strong rotation is
observed in the future venous pole, while very little rotation is
observed in the future arterial pole.
32 The different rates of heart
tube rotation result in torsion of the cardiac tube, and biomechanical
models have proposed that rotation at one of the poles of the heart
tube is sufﬁcient to drive dextral looping.
37,38 The use of forward
genetic screens to identify mutants with speciﬁc defects in cardiac dis-
placement and looping will help to identify critical regulators of the
looping process in the future.
During cardiac looping, the ventricle and atrium become morpho-
logically distinguishable as bean-shaped chambers with a distinct outer
curvature and inner curvature, through a process referred to as
chamber ballooning.
39 Expression of natriuretic peptide type A (nppa)
marks the outer curvature myocardium in both mouse and ﬁsh
hearts and is ﬁrst detected at 28 hpf.
40 During ventricular chamber
emergence, regionally conﬁned cell shape changes are observed in
the outer curvature. The outer curvature cells are typically oriented
with their long axes perpendicular to the arterial–venous axis,
suggesting that cardiomyocyte elongation plays a substantial role in
creating the characteristic convex shape of the outer curvature.
40
Furthermore, blood ﬂow through the developing ventricle promotes
cardiomyocyte elongation and thereby encourages establishment of
the outer curvature, while intrinsic contractility restricts cardiomyo-
cyte elongation, preventing cardiac dilatation.
40
2.6 Atrioventricular valves
Cardiac valves are critical for proper functioning of the vertebrate
heart, and malformation of the valves underlies many forms of
human congenital and adult-onset heart diseases, such as aortic or
pulmonary valve stenosis, bicuspid aortic valve, mitral valve prolapsed,
and Epstein’s anomaly. The presence of valves between the ventricle
and atrium prevents blood from ﬂowing back from the ventricle to
the atrium when the ventricle contracts. Cardiac valve formation
has been most extensively studied in chick and mouse embryos (for
recent review see Combs and Yutzey
41). In amniotes, valvulogenesis
starts with the formation of an endocardial cushion in the atrioventri-
cular (AV) canal. Endocardial cells overlying this local swelling of the
cardiac jelly (extracellular matrix located between the myocardium
and endocardium) receive signals from the AV canal myocardium to
undergo an epithelial-to-mesenchymal transition. Delaminated endo-
cardial cells migrate into the cardiac jelly and ﬁll these local swellings
by proliferation. In the zebraﬁsh heart, the ﬁrst signs of endocardial
transdifferentiation are observed at 36 hpf, when squamous endocar-
dial cells located in the future AV canal become cuboidal and start to
express the cell adhesion molecule Dm-grasp.
42 By 48 hpf, endocar-
dial cells lining the AV canal form a single layer of cuboidal cells
that express Dm-grasp, in contrast to the squamous
Dm-grasp-negative endocardial cells lining the chamber myocardium.
At this stage, the Dm-grasp-positive endocardial cells form cellular
protrusions that extend into the cardiac jelly. Recent studies employ-
ing live high-speed imaging using single-plane illumination microscopy
revealed that although the endocardial cells form a multicellular
cushion structure, these endocardial cells remain epithelial and do
not delaminate in the manner described for endocardial cushion
cells in the amniote heart.
43 These results suggest that the endocardial
cushions in zebraﬁsh do not form by epithelial-to-mesenchymal tran-
sition, but instead by invagination of the endocardial cells.
44 Although
the mechanism by which the endocardial cushions arise in zebraﬁsh
appears to differ from amniotes, the molecular signals regulating the
process have been conserved. As in amniotes, Notch, NFAT, ErbB
and Tgf-b signalling are required for cardiac valve formation in zebra-
ﬁsh.
42–45 In addition to the above-mentioned regulators, ectopic
Wnt/b-catenin signalling induces endocardial proliferation and the
expression of has2, which is required for epithelial-to-mesenchymal
transition in the endocardial cells of the mouse AV canal.
46 To gain
a better understanding of valve formation in amniotes and zebraﬁsh,
it will be important to investigate the cellular processes that are regu-
lated by these signalling pathways.
By 105 hpf, the endocardial cushions have enlarged and differen-
tiated into valve leaﬂets. The AV valve leaﬂets, which are composed
of two layers of cells separated by a layer of ﬁbronectin-containing
extracellular matrix, extend into the lumen of the ventricle.
42,44 In
addition to genetic factors, environmental factors also inﬂuence
valve formation. In mutant embryos that display defects in early myo-
cardial function, such as silent heart/sil, which lack a heartbeat due to
mutation of cardiac troponin T (tnnt2), or cardiofunk/cfk, encoding a
novel sarcomeric actin expressed in the embryonic myocardium,
cardiac valve formation is impaired.
47 Furthermore, blood ﬂow
through the heart results in endothelial sheer stress, which is required
for correct cardiac valve formation.
48 Oscillating blood ﬂow through
the AV canal induces the expression of klf2, a shear-reponsive gene, in
the endocardial cushion cells. klf2 acts upstream of Notch1 and is
required for the cell shape changes and invagination process observed
in the endocardial cushions.
2.7 Conduction system
Cardiomyocyte contraction is ﬁrst observed when the linear heart
tube is being formed. Initial cardiomyocyte contractions are irregular
and unco-ordinated, but show a co-ordinated pattern once the heart
tube has formed. Contractions are initiated at the venous pole. Owing
to slow conduction of the impulse throughout the heart tube, these
contractions are initially peristaltic. As the heart develops, the rate
of contractions increases and changes from a peristaltic contraction
into a sequential contraction of the atrium and ventricle. In 1949,
Patten ﬁrst observed that in the chick heart the most recent cardio-
myocytes added to the venous pole possess an intrinsically higher
contraction rate than the part of the cardiac tube already formed.
49
As the part of the cardiac tube with the highest contraction rate at
any given phase of development sets the rate for the entire heart,
he concluded that the pacemaker is always located in the part of
the heart that was added most recently. By expressing light-gated
ion channels in zebraﬁsh, the pacemaker or sino-atrial node was
recently located at the inner curvature of the venous pole, the
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11,50 Interest-
ingly, the cardiomyocytes added to the venous pole express isl1,
which encodes a LIM-homeodomain-containing transcription factor
also expressed in motorneurons. Zebraﬁsh isl1 mutant embryos
display bradycardia and arrhythmias, suggesting a role for Islet-1 in
the pacemaking cells.
11
During cardiac looping (36–48 hpf), a slowing of the electrical
pulse is observed in the region of the AV canal, also referred to as
AV delay, resulting in a contraction delay at the AV boundary.
51,52
This AV delay coincides with the transition from a peristaltic contrac-
tion of the heart tube into a more efﬁcient sequential contraction of
the atrium followed by the ventricle. Cardiomyocytes are positioned
circumferentially around the AV canal, suggesting that morphological
differences between cardiomyocytes of the AV canal and the
chamber myocardium contribute to the AV delay. In cloche mutants,
which lack all endothelium including the endocardium, the conduction
delay in AV canal myocardium is not observed.
51 This observation
suggests that endocardium-derived signals cause the overlying myo-
cardium to differentiate into slow- and fast-conducting myocardium.
Knock-down of notch1b or neuregulin, which are expressed in the
endocardium, also results in a loss of the AV conduction delay in
the AV canal myocardium.
51 The role of endocardial Neuregulin
seems conserved in other species, because in mouse embryos Neure-
gulin is expressed in the endocardium and can promote the formation
of the cardiac conduction system.
53,54 Several signalling pathways and
transcription factors expressed in the AV canal myocardium have
been identiﬁed that are required to maintain a primitive and slow-
conducting AV canal myocardium. For instance, expression of the
T-box transcription factor tbx2b in the AV canal myocardium is
required for the observed AV conduction delay.
55 Analogous to its
activity in the mouse heart, Tbx2b prevents the expression of nppa,
a marker for cells belonging to the fast-conducting outer curvature
of the chamber myocardium. Several factors have been identiﬁed
that regulate tbx2 expression in the AV canal. Zebraﬁsh bmp4 is
expressed in the AV canal, and Bmp signalling activity regulates
expression of the tbx2b in the AV canal myocardium.
55,56 Further-
more, in apc mutant embryos, in which Wnt signalling is enhanced,
bmp4 expression is expanded, suggesting that Wnt signalling in the
myocardium regulates bmp4 and tbx2 expression in the AV canal.
Indeed, myocardial contraction remains slow, without any obvious
AV delay, in apc mutant hearts.
56 Expression of tbx2b in the AV
canal is also controlled by the forkhead transcription factor foxn4,
and consequently loss of foxn4 leads to a loss of the AV conduction
delay.
55
2.8 Epicardium
During linear heart tube and looping stages, the heart wall is com-
posed of only two cellular layers, the myocardium and endocardium.
A third cellular layer, the epicardium, which covers the outside of the
myocardium, develops from an extracardiac population of cells called
the pro-epicardium. The pro-epicardium can be distinguished mor-
phologically at 48 hpf as a group of spherical cells located in close
proximity of the ventral wall of the looped heart (Figure 1G). At
72 hpf, it has increased in size and starts to spreads over the myocar-
dial surface of the looped heart.
57,58 Molecularly, the pro-epicardium
is characterized by the onset of expression of wt1, tbx18 and tcf21 at
40–48 hpf. Speciﬁcation of the pro-epicardium requires a Bmp ligand,
which is not derived from the liver bud as was previously assumed.
58
bmp4 is expressed in the myocardium and is required for
pro-epicardium speciﬁcation, suggesting that a cardiac Bmp signal
induces pro-epicardium speciﬁcation. Independently from Bmp signal-
ling, tbx5 expression in the lateral plate mesoderm during the early
somite stages is also required for pro-epicardium speciﬁcation.
58
Although it is well described in zebraﬁsh, chick and mouse embryos
that extracardiac pro-epicardial cells form a bridge to the myocardium
and spread onto it, thus far the instructive molecular signals driving
this process are largely unknown.
In the adult heart, the epicardium is a squamous epithelium, which
forms a smooth surface covering the entire heart wall. Upon injury of
the heart, for example by dissection of the apex of the ventricle, the
zebraﬁsh epicardium responds by elevating expression of the embryo-
nic epicardial markers tbx18 and raldh2. This suggests that an embryo-
nic gene expression programme in the epicardium is activated in
response to injury.
59 This activation starts throughout the entire ven-
tricle and gradually becomes localized to the apex. The activated epi-
cardial cells proliferate and undergo epithelial-to-mesenchymal
transition, which requires the platelet-derived growth factor.
60 The
developmentally activated epicardial cells then invade the newly
formed myocardium at the site of injury and create a dense vascular
network that is likely to encourage regeneration.
59,60
3. Zebraﬁsh to model human
congenital and acquired cardiac
diseases
3.1 Congenital heart defects
Currently, approaches for discovering monogenetic factors involved
in human congenital heart defects (CHDs) include pedigree studies
and candidate screens. Classical forward genetic human pedigree
studies have thus far provided limited insight into the genetic causes
of CHDs. More recently, reverse genetic approaches have been
used to identify single nucleotide polymorphisms (SNPs) in candidate
genes. In such an approach, candidate genes are typically selected
from pre-existing knowledge obtained from basic scientiﬁc studies
using various model organisms.
61–63 This knowledge can come
from the zebraﬁsh model, as demonstrated by a study in which
mutations where identiﬁed in the Nodal co-receptor EGF-CFC/
CRYPTIC in patients with severe congenital visceral laterality
defects.
64 In a recent candidate screen, which consisted of sequencing
the coding regions (exons) of 32 candidate genes of 190 CHD
patients, a number of novel and potential genetic determinants of
atrioventricular valve and septum (AVS) defects were identiﬁed.
63
By using two different algorithms, which can predict the affect of
the mutation on protein function, 11 patient-speciﬁc coding SNPs
(cSNPs) were identiﬁed that are likely to be damaging. One such
cSNP was identiﬁed in GATA4, for which a causal relation with AVS
defect was demonstrated in other studies.
65 The 10 remaining
cSNPs were found in genes not previously linked to AVS defects in
human subjects such as ALK2, ALK3, APC, ECE2, EGFR, ERBB3,
FOXP1, ADAM19, and UGDH. Expression of the patient-speciﬁc
ALK2 L343P variant in zebraﬁsh showed that this results in a malfor-
mation of the AV canal and compromised expression of endocardial
cushion markers. Additionally, in vivo studies demonstrated either
reduced or dominant-negative activity of the disease-related ALK2 (a
BMP receptor) variants.
63,66 A role for UGDH, encoding a UDP-
glucose dehydrogenase, in cardiac valve formation was demonstrated
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mutation in the zebraﬁsh ugdh gene, does not form proper AV
valves.
21,67 The complex process of AV valve and septum formation,
with its multifaceted stages and various signalling pathways involved,
would indicate that aberrant AVS development indeed can occur at
numerous steps in the process. Array comparative genomic hybridiz-
ation and next-generation sequencing are new technologies with
promising possibilities for detecting genomic alterations in CHD
patients.
68 An advantage of the candidate gene approach is that
genetic variants can be identiﬁed relatively rapidly and in small pedi-
grees or even single individuals. Next-generation exome or whole-
genome sequencing will change the landscape of personalized diag-
nostics, through cataloguing all genomic variations of a single affected
individual.
69
The major short-coming of candidate screening, array comparative
genomic hybridization, and next-generation sequencing still remains
that from any variant discovered within an affected individual or popu-
lation it remains unknown whether the variant is potentially disease
causing or not. As a consequence, testing the potential in vivo effect
of the identiﬁed variants is important though challenging. In cases
where genotype–phenotype information on the affected families is
lacking or not conclusive, the zebraﬁsh model has proved itself as a
useful tool in such studies.
63,64
3.2 Cardiomyopathies
Human cardiomyopathies are diseases that primarily affect the myo-
cardium. The two most prevalent forms are dilated cardiomyopathy
(DCM) and hypertrophic cardiomyopathy (HCM). DCM is a syn-
drome characterized by enlargement of one or both ventricles of
the heart, accompanied by diminished myocardial contractility. HCM
is deﬁned as thickening of the myocardium in the left and/or right ven-
tricle in the absence of any other diseases that cause myocardial
hypertrophy, such as high blood pressure or storage diseases. HCM
is considered to be multifactorial with a strong genetic inﬂuence,
while DCM has a genetic contribution in at least 30% of all cases.
DCM is associated with mutations in genes encoding cytoskeletal or
contractile proteins. One mechanism underlying the development of
DCM is defective cardiac stretch sensing.
70 Several zebraﬁsh
mutants have been identiﬁed that display heart phenotypes resem-
bling the features of human cardiomyopathies, and their characteriz-
ation has provided a better understanding of the human disease. In
addition, identiﬁcation of the genes affected in these mutants has pro-
vided novel candidate genes that allow further characterization of the
genetics of human cardiomyopathies (summarized in Table 1).
In a large-scale screen for recessive lethal mutations due to cardiac
dysfunction, the silent heart/sil and pickwick/pik mutants were ident-
iﬁed.
21 The hearts of homozygous pik and sil embryos develop nor-
mally but are poorly contractile from the ﬁrst beat. Positional
cloning of two sil alleles revealed inactivating mutations in the tnnt2
gene encoding cardiac troponin T.
71 Mutations in human TNNT2
cause DCM and familial HCM, the leading cause of sudden death in
young athletes, making the sil/tnnt2 mutant an excellent model to
study the role of Tnnt2 in cardiac function and disease. Positional
cloning of the pik locus revealed a causative mutation in the ttn
gene encoding the large sarcomeric titin protein.
72 The titin
protein spans the half-sarcomere from Z-disc to M-band and is
required for proper sarcomere assembly, as well as confering elasticity
on the sarcomeres. Cardiomyocytes devoid of a functional titin
protein are elongated and thin when transplanted into a wild-type
heart, resembling a DCM phenotype in zebraﬁsh.
72 Notably, in a
large human pedigree a 2 bp insertion in the TTN gene was identiﬁed,
causing a frameshift and subsequent truncation of titin, which was
strongly associated with autosomal dominant DCM in the studied
family.
73
The same large-scale screen in which the sil and pik mutants were
identiﬁed also led to the identiﬁcation of the main squeeze/msq
mutant, which displays ventricle dysfunction starting at 60–
70 hpf.
21 In an independent screen, the lost-contact/loc mutant was
identiﬁed, which is allelic with the msq mutant.
61 Positional cloning
of the loc and msq alleles revealed a premature stop mutation and
a mis-sense mutation, respectively, in the gene encoding
integrin-linked kinase (Ilk).
61,74 Integrins interact with laminin
.......................................................................................................................................................................................
Table 1 Zebraﬁsh cardiac mutants with related human disease
Zebraﬁsh gene
name
Zebraﬁsh loss-of-function phenotype Human
gene name
Related human heart disease Reference
one-eyed-pinhead/
egf-cfc
Reduced mesendoderm differentiation,
visceral laterality defects and cardia biﬁda
CRYPTIC Dextrocardia, transposition of the great arteries,
double-outlet-right-ventricle, AVS defect
6,64,86
lost-a-ﬁn/alk8 Unlooped heart with reduced atrium ALK2 AVS defect, mitral valve malformation 36,17,18,63,66
jekyll/ugdh AV valves fail to form UGDH AVS defect 63,67
apc Unlooped heart with hyperplastic endocardial
cushions
APC AVS defect 46,63
silent-heart/tnnt2 Poorly contractile ventricle and atrium TNNT2 DCM and HCM 71
pickwick/ttn Poorly contractile ventricle and atrium TTN DCM 72,73
lost-contact/
main-squeeze/ilk
Reduced contractility and aberrant
cardiomyocyte shape, dilated and reptured
blood vessels
ILK DCM 21,61,74
laminin alpha 4 Genetic interaction with lost-contact/ilk LAMA4 DCM 61
nexilin/nexn Disturbed sarcomere integrity and dilated
heart
NEXN DCM 62,75
chap Disturbed sarcomere integrity and dilated
heart
CHAP Unknown 76
Zebraﬁsh to study cardiac development and disease 285present in the extracellular matrix, and genetic studies in zebraﬁsh
showed that loc/ilk interacts genetically with lama4.
61 Cardiomyo-
cytes devoid of a functional integrin-linked kinase protein appear
stretched and thin when transplanted into a wild-type heart. Based
on these results, mutations in human ILK and LAMA4 were identiﬁed
in patients with DCM.
61
Within the sarcomeres, the myoﬁlaments are anchored to the
Z-disc, the mechanical integration site of heart muscle cells. Several
key molecules that enable the Z-disc persistently to withstand the
extreme mechanical forces during muscle contraction have been
identiﬁed, such as MLP, T-Cap, ILK, a-actinin, and integrins. Recently,
several novel Z-disc proteins have been identiﬁed, whose function has
been studied in vitro and in vivo using zebraﬁsh. Loss of nexilin
(encoded by nexn) in zebraﬁsh led to perturbed Z-disc stability and
heart failure.
62 To evaluate the role of nexilin in human heart
failure, two independent candidate screens were performed on indi-
viduals with either DCM or HCM, and several mutations in NEXN
were found.
62,75 Another new Z-disc protein, encoded by Chap
(cytoskeletal heart-enriched actin-associated protein), is expressed
in differentiating heart and skeletal muscle.
76 Interestingly, in addition
to its sarcomeric localization, Chap is also able to translocate to the
nucleus. Knockdown of chap in zebraﬁsh results in aberrant cardiac
and skeletal muscle development and function.
Many regulatory elements that drive expression of cardiac genes
are being identiﬁed using chromatin immunoprecipitation combined
with high-throughput sequencing (ChIP-Seq). ChIP-Seq is used to
identify the cis-acting targets of DNA-associated proteins. Recently,
a ChIP-Seq-based genome-wide study aimed at discovering human
heart enhancers was published.
77 Validation of these enhancers
in vivo in mouse and zebraﬁsh resulted in a validation rate of 62%,
demonstrating the usefulness of the zebraﬁsh model in veriﬁcation
of results obtained by large-scale genome projects.
3.3 Gene targeting of novel cardiac genes
Various studies have described the isolation of novel proteins that are
expressed in cardiac muscle with a previously unknown func-
tion.
62,76,78–80 Whilst in vitro experiments provide valuable infor-
mation with respect to the cellular distribution or effects on
muscle differentiation of such novel proteins, essential information
about their in vivo role during cardiac development or function
requires loss-of-function studies in a whole organism. Currently,
there are several technologies available to perform loss-of-function
studies in zebraﬁsh (reviewed by Skromne and Prince
81). Here, I
will list and explain brieﬂy the most commonly used technologies
for reverse genetics, also known as the ‘phenotype-driven approach’.
Protein activity can be perturbed using small chemicals that are water
soluble and are efﬁciently taken up by the embryo when added to the
embryo medium. This approach can work well for proteins with
enzyme activities, such as kinases, or to prevent protein–protein
interactions. The advantage of a chemical approach is that the chemi-
cal can be added to the medium at the relevant stages to study
cardiac development or cardiac function, preventing earlier develop-
mental defects. Additionally, chemicals can also be washed out from
the embryo, resulting in a tight temporal control. A drawback of the
chemical approach is the limited availability of chemicals that block
speciﬁc protein function, making this technology suitable only for
well-characterized proteins. In addition, the speciﬁcity of the chemical
for its target protein(s), depending on how numerous they are, is
often a problem. Thus far, the most frequently used technology to
perturb the function of uncharacterized proteins is the use of anti-
sense morpholino oligonucleotides.
82 Morpholino oligonucleotides
are short chains of about 25 modiﬁed nucleotides, which make
them resistant to RNAse degradation. Morpholinos do not degrade
their RNA targets, but instead act via a steric blocking mechanism.
Depending on the oligo sequence, they can either block translation
initiation, by targeting the 5′ UTR through the ﬁrst 25 bases of
coding sequence, or modify pre-RNA splicing, by targeting splice
junctions. The oligonucleotides are injected into the oocyte directly
after fertilization and can be effective up to 3–4 days post fertiliza-
tion. Although the oligonucleotides are designed to target the gene
of interest exclusively, they do not always result in an efﬁcient knock-
down of the gene of interest and are also prone to off-target effects.
To address whether the observed phenotypes after morpholino
injection are due to knock-down of the gene of interest, proper
control experiments must be performed.
83 As zebraﬁsh have a
partly duplicated genome, it often contains two paralogous genes
when the mouse or human genome contains a single gene. As a con-
sequence, one would need to knock down both genes to observe the
complete loss-of-function phenotype. To prevent off-target effects or
to study cardiac gene function at stages beyond the 3- to 4-day-old
embryo, it is possible to use target-selected mutagenesis, which com-
prises random chemical mutagenesis, followed by screening for
mutations in target genes.
84 This approach results in a stable
mutant in the gene of interest, resolving the variability and off-target
problems associated with the previously described technologies. Its
disadvantage is the requirement for a large ﬁsh facility and the avail-
ability of a high-throughput screening platform, which limits its appli-
cation to larger research groups or centres. More recently, the use of
zinc ﬁnger nucleases (ZFNS) has been introduced as a new technol-
ogy for gene targeting in zebraﬁsh (reviewed by Urnov
85). The ZFN
technology is based on the combined use of sequence-dependent
DNA-binding domains of a speciﬁc class of eukaryotic transcription
factors, zinc ﬁnger proteins, together with the nuclease domain of
the FokI restriction enzyme. Owing to their modular approach,
ZFNs have the advantages of DNA-binding speciﬁcity and the ﬂexi-
bility of zinc ﬁnger proteins and can be targeted to speciﬁc sites
within the genome. ZFN technology combines the advantages of
the speciﬁcity of gene targeting with the inheritability of the gener-
ated gene disruption. Its drawbacks are the limited chance of
ﬁnding ZFN targets sites in small genes and the amount of work
that is required to select the proper ZFNs that efﬁciently recognize
and cleave the target sequence. Thus far, the ZFN technology has
not been used to study the loss-of-function phenotype of novel
cardiac genes.
4. Conclusion
In the last decade, the zebraﬁsh model has developed into a very
powerful model to study cardiac development. Owing to the efforts
of forward genetic screens, many novel factors and regulatory mech-
anisms have been identiﬁed that have essential roles during cardio-
genic speciﬁcation and differentiation, migration of cardiac
progenitor cells, heart tube morphogenesis, and cardiac function. By
developing new and more specialized assays, forward genetic screen
efforts will continue to contribute new insights to the ﬁeld of
cardiac development in the years to come. In addition, the growing
toolbox that allows speciﬁc gene disruptions in combination with
tissue-speciﬁc and inducible expression systems will make the
J. Bakkers 286zebraﬁsh for many researchers the preferred model organism to
study their gene of interest. More recently, the zebraﬁsh has been
used to study mechanisms leading to human cardiac diseases and to
model human congenital and acquired cardiac diseases. Predictably,
this ﬁeld will grow rapidly in the coming years owing to the increase
in sequencing efforts, the growing interest in cardiac diseases, and the
improved availability of the zebraﬁsh model for clinical and basic
researchers interested in studying cardiac diseases.
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